Re: YMB
They are irrelevant. This is no longer a trading stock. Risk of losses from shorting is rising as risk to long shares is dropping. Holding short positions is now moving from a money maker to a money loser with margin calls and interest payouts devaluing their positions further. The attempt to undo the gains this week at end of day today was thwarted. The gains we finally saw this week were from controlled volume based on positive results and analyst comments. And, the company comment that Japan approval is a "near term" catalyst was telling. Finally, in the earnings call the new CMO rattled off three additional new possibilities for Brensocatib in addition to COPD, Asthma and Brochiectasis - that we have never heard of before - so possibilities just keep growing.